tetano
Editor, Senior Moderator
SN Compr Clin Med
. 2022;4(1):88.
doi: 10.1007/s42399-022-01168-3. Epub 2022 Apr 1.
mRNA Vaccines as an Efficient Approach for the Rapid and Robust Induction of Host Immunity Against SARS-CoV-2
Rashed Noor[SUP] 1 [/SUP]
Affiliations
Abstract
Among the currently used COVID-19 vaccines, the mRNA-based vaccines drew the interest of the scientists because of its potent and versatile nature in mitigating the disease efficiently through increased translation as well as the robust modulation of the innate and adaptive immune responses within the host. The naked or lipid encapsulated mRNAs are usually optimized in order to formulate the vaccine. One of the interesting advantage of using mRNA vaccines is that such platform can even be used to mitigate other infectious diseases like influenza, zika, and rabies. However, the leading COVID-19 mRNA vaccines, i.e., mRNA-1273 and BNT162b2, have already been noticed to possess around 95% efficacy in provoking both the humoral and cell mediated immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, causing the ongoing COVID-19 pandemic.
Keywords: COVID-19 mRNA vaccines; Immunity; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Vaccine efficiency; mRNA 1273 vaccine; mRNA BNT162b2 vaccine.
. 2022;4(1):88.
doi: 10.1007/s42399-022-01168-3. Epub 2022 Apr 1.
mRNA Vaccines as an Efficient Approach for the Rapid and Robust Induction of Host Immunity Against SARS-CoV-2
Rashed Noor[SUP] 1 [/SUP]
Affiliations
- PMID: 35402783
- PMCID: PMC8975617
- DOI: 10.1007/s42399-022-01168-3
Abstract
Among the currently used COVID-19 vaccines, the mRNA-based vaccines drew the interest of the scientists because of its potent and versatile nature in mitigating the disease efficiently through increased translation as well as the robust modulation of the innate and adaptive immune responses within the host. The naked or lipid encapsulated mRNAs are usually optimized in order to formulate the vaccine. One of the interesting advantage of using mRNA vaccines is that such platform can even be used to mitigate other infectious diseases like influenza, zika, and rabies. However, the leading COVID-19 mRNA vaccines, i.e., mRNA-1273 and BNT162b2, have already been noticed to possess around 95% efficacy in provoking both the humoral and cell mediated immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, causing the ongoing COVID-19 pandemic.
Keywords: COVID-19 mRNA vaccines; Immunity; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Vaccine efficiency; mRNA 1273 vaccine; mRNA BNT162b2 vaccine.